Puma Biotech granted Orphan Drug status for lung cancer candida | Seeking Alpha
Puma Biotechnology unveils Phase II breast cancer trial design
A Top Puma Bio Exec Resigns Ahead of FDA Panel, Analysts Defend With Conflicting Stories - TheStreet
Articles about Puma Biotechnology
Puma Biotechnology Surging
Puma Biotechnology reports interim SUMMIT results for neratinib | Drug Discovery News
Puma Biotechnology (NASDAQ:PBYI) Stock Rating Upgraded by StockNews.com - MarketBeat
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotechnology
Why Puma Biotechnology, Inc. Stock Crashed 37% in March
Puma Biotechnology Inc (PBYI) Stock News | Stock Titan
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Puma Biotechnology (PBYI) Price Target Increased by 5.26% to 5.10
Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference
Puma Biotechnology Inc (PBYI) Stock Message Board | InvestorsHub
Puma Biotechnology Reports Third Quarter 2022 Financial Results | Business Wire
Puma Biotechnology Inc (PBYI) Stock: What Does the Chart Say Tuesday?
Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference
Puma Biotechnology Crashed After Lagging More Bullish Views For Breast Cancer Drug Nerlynx | Stock News & Stock Market Analysis - IBD
Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer | Business Wire
Puma Biotechnology
PBYI Stock Price and Chart — NASDAQ:PBYI — TradingView
Puma Biotech agrees to pay investors $54.2 mln in fraud case | Reuters
Puma Biotechnology falls more than 20%
